Alpha 2.0
Login Register
» Articles » PMID: 20010173

Single-center Phase II Trial of Transarterial Chemoembolization with Drug-eluting Beads for Patients with Unresectable Hepatocellular Carcinoma: Initial Experience in the United States

Overview
Journal Cancer J
Specialty Oncology
Date 2009 Dec 17
PMID 20010173
Citations 53
Authors
Diane K Reyes
Josephina A Vossen
Ihab R Kamel
Nilofer S Azad
Tamara A Wahlin
Michael S Torbenson
Michael A Choti
Jean-Francois H Geschwind
Affiliations
Soon will be listed here.
Abstract

Purpose: This prospective phase II pilot study evaluated safety and efficacy of transarterial chemoembolization (TACE) with drug-eluting beads (DEBs) loaded with doxorubicin in patients with unresectable hepatocellular carcinoma (HCC).

Methods: Twenty patients with unresectable HCC (75% Child's A, 95% Eastern Cooperative Oncology Group performance status 0 to 1, 60% Barcelona Clinic Liver Cancer C, tumor size 6.9 cm) underwent 34 DEB-TACE sessions. Primary endpoints were tumor response, assessed by contrast-enhanced magnetic resonance imaging at 1 month after treatment, using size (response evaluation criteria in solid tumors [RECIST]), contrast-enhancement (European Association for the Study of the Liver) and apparent diffusion coefficient values, and safety assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Secondary endpoints included feasibility, progression-free survival, and overall survival.

Results: DEB-TACE was successfully performed in 34 sessions and demonstrated a favorable safety profile. On initial (1 month) postprocedural magnetic resonance imaging, treated lesions had a mean decrease in size of 4% (P = 0.1129). Using RECIST, partial response was achieved in 2 patients (10%), and 18 patients (90%) had stable disease. Treated tumors demonstrated a mean decrease in contrast enhancement of 64% (P < 0.0001). By European Association for the Study of the Liver criteria, 12 patients (60%) had objective tumor response, and 8 (40%) had stable disease. No patients had progression of a treated lesion while undergoing treatment. At 6 months, the disease control rate was 95% using RECIST. Overall survival rates at 1 and 2 years were 65% and 55%, respectively; median overall survival was 26 months.

Discussion: DEB-TACE is safe and effective in achieving local tumor control in patients with unresectable HCC.

Citing Articles

Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients.

Arendt N, Kopsida M, Khaled J, Sjoblom M, Heindryckx F Ther Adv Med Oncol. 2025; 17:17588359251316663.

PMID: 39926261 PMC: 11806495. DOI: 10.1177/17588359251316663.

5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis.

Wei M, Zhang P, Yang C, Luo M, Zeng C, Zhang Y Sci Rep. 2024; 14(1):25588.

PMID: 39462077 PMC: 11513126. DOI: 10.1038/s41598-024-77531-2.

Efficacy and safety of CalliSpheres drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study.

Wu X, Ying S, Huang J, Shi C, Ji J, Peng Z Transl Cancer Res. 2022; 8(4):1199-1216.

PMID: 35116862 PMC: 8797412. DOI: 10.21037/tcr.2019.06.44.

Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.

Wang Z, Mu K, Lv Y, Zhao L, Li B, Hao Y Ir J Med Sci. 2022; 191(6):2493-2499.

PMID: 35064533 DOI: 10.1007/s11845-021-02851-5.

Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).

Mukund A, Bhardwaj K, Choudhury A, Sarin S J Clin Exp Hepatol. 2021; 11(6):674-681.

PMID: 34866846 PMC: 8617544. DOI: 10.1016/j.jceh.2021.02.003.

References
1.
Lo C, Ngan H, Tso W, Liu C, Lam C, Poon R . Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35(5):1164-71. DOI: 10.1053/jhep.2002.33156. View
2.
Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S . Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging. 2007; 33(5):512-9. DOI: 10.1007/s00261-007-9334-x. View
3.
Geschwind J, Ramsey D, Cleffken B, van der Wal B, Kobeiter H, Juluru K . Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol. 2003; 26(2):111-7. DOI: 10.1007/s00270-002-2524-6. View
4.
Geschwind J, Artemov D, Abraham S, Omdal D, Huncharek M, McGee C . Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol. 2000; 11(10):1245-55. DOI: 10.1016/s1051-0443(07)61299-8. View
5.
Lee K, Liapi E, Vossen J, Buijs M, Ventura V, Georgiades C . Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008; 19(10):1490-6. PMC: 2747287. DOI: 10.1016/j.jvir.2008.06.008. View